Infections due to \textit{Pseudomonas fulva} remain a rare but emerging concern. A case of ventriculitis due to \textit{Enterobacter cloacae} and \textit{Pseudomonas fulva} following placement of an external ventricular drain is described. Similar to other reports, the organism was initially misidentified as \textit{Pseudomonas putida}. The infection was successfully treated with levofloxacin.
**Case Report**

**Pseudomonas straminea** (98.63%). Because the species match to *P. fulva* was >99% and the separation from the next most similar species was greater than 0.8%, the identification as *P. fulva* was considered definitive (1). An identification of *P. putida* was not presented as an option by the sequencer for this isolate. When the obtained sequence was applied to a GenBank search, the first identification was *P. fulva*, with a 99% similarity match to type strain *P. fulva* NRIC 0180 with 3 mismatches in 482 bp. The next nearest species match was to *Pseudomonas fluorescens*. Even though the percentages for both identifications were 99%, the total score for *P. fulva* was 8 points greater than for *P. fluorescens*. The nearest match to any reference or type strain of *P. putida* using BLAST was 97% to *P. putida* strain KT2440.

Biochemical characterization using the Biolog OmniLog identification system (Biolog, Inc., Hayward CA) and GEN III MicroPlate was done in triplicate and resulted in a metabolic fingerprint consistent with an identification of *P. fulva* with probabilities of 77% (excellent identification), 56%, and 55% (good identification). No other species met the 50% probability required for acceptable species identification. Additional tests showed that the isolate failed to grow at 42°C and did not fluoresce when examined under UV light from a Wood’s lamp.

The *P. fulva* isolate was susceptible to all antibiotics tested: amikacin, aztreonam, ceftazidime, gentamicin, levofloxacin, meropenem, piperacillin-tazobactam, and tobramycin. The antibiotics tested, the *E. cloacae* isolate was resistant only to ampicillin. After initial positive CSF cultures, the patient was started on intravenous (i.v.) levofloxacin (750 mg i.v. daily) and rifampin (600 mg i.v. daily) while awaiting final species identification. The fever resolved, the CSF WBC count improved, the EVD was removed, and rifampin was discontinued on the third day of this regimen. The patient completed an additional 16 days of oral levofloxacin (750 mg per day). The patient remained afebrile and was without evidence of recurrence in follow-up approximately 1 month after completion of antibiotic therapy.

*P. fulva* is a Gram-negative rod that was initially grouped with other plant-inhabiting *Pseudomonas* species that also produce a yellow pigment. The classification was revised based on 16S rRNA gene sequences, and *P. fulva* is now phylogenetically located in the *P. putida* group, which also includes *Pseudomonas monteilii*, *Pseudomonas mosselii*, *Pseudomonas oryzihabitans*, *Pseudomonas plecoglossica*, and *P. putida* (2). *P. fulva* cells measure 0.6 to 0.8 by 1.4 to 1 μm, have rounded ends, and are motile with polar flagella. Growth occurs at temperatures between 4°C and 37°C, but *P. fulva* does not grow at 41°C. Typically, *P. fulva* colonies are smooth and wet. Although catalase and oxidase are produced, the oxidase reaction has been described as weakly positive (3, 4). As with other *Pseudomonas* species, metabolism is strictly aerobic. Key biochemical characteristics include production of arginine dihydrolase and lack of reduction of nitrate to nitrite. In contrast to its closely related species, *P. fulva* produces a water-insoluble yellow pigment and does not assimilate malonate or *m*-hydroxybenzoate while *P. putida* produces a water-soluble fluorescent pigment and does assimilate the two compounds.

While *P. fulva* has been identified mainly in natural environments, including rice and petroleum fields from which it was initially isolated (5), few cases of *P. fulva* infection in human have been documented. Thus far, two previous cases have highlighted findings of *P. fulva* in human CSF and bloodstream. Comparing these two reports with our own finding revealed important similarities that support our conclusion and nuances in the presenting characteristics that highlight the complexity of *P. fulva* as an emerging infection.

Similar to the two previous reported human cases of *P. fulva*, the initial identification efforts misidentified the organism as *P. putida*. Almuzara et al. relied on the Vitek 2 system and API 20 NE, both of which indicated the presence of *P. putida* (4). Similarly, Seok et al. also originally identified their isolate as *P. putida* by using the Vitek 2 and ID 32 systems (3). Our specimen was subjected to the MicroScan WalkAway Plus Neg Breakpoint Combo Panel Type 41, API 20 NE, and Vitek MS, and all three systems led to *P. putida* identification. Consistent with the initial identifications in the CSF and bloodstream cases, which had relatively high probabilities of identification of *P. putida* ranging from 99.0% on the Vitek2 system in the report by Seok et al. to 99.9% from the ID 32 GN system, biochemical testing of our isolate on the MicroScan (99.2%) and API 20 NE (98.2%) also produced high probabilities. We postulate that the initial identifications of our isolate may have suggested *P. putida* due to limited distinguishing biochemicals on the panels and a database content not inclusive of *P. fulva*. The API 20 NE strip does not contain any biochemicals that distinguish *P. putida* from *P. fulva*, and the MicroScan panel contains three distinguishing biochemicals, inositol, sucrose, and malonate, none of which are assimilated by *P. fulva*, and the panel gave the expected negative reactions. The Vitek MS does not have *P. fulva* mass spectra in the reference database and generated an identification of *P. putida*, but with a probability of only 81.9%.

Similar to the other two cases, we questioned the identification of *P. putida* due to the inconsistent phenotypic and biochemical characterization of the isolates with the typical *P. putida* features. Colonies from all three reports were brownish yellow in color, due to production of a water-insoluble pigment, which more closely resembled *P. fulva*. The isolates were arginine dihydrolase positive, and further substrate utilization profiles showed that the isolates were malonate negative. Similar to our observation of no growth of our isolate at elevated temperatures, the isolates reported by both Seok et al. and Almuzara et al. also did not grow at 41°C (2, 3). These characteristics were consistent with the identi-
fication by Uchino et al. of *P. fulva* (2). In considering oxidase tests, the CSF specimen isolated by Seok et al. (3) was oxidase negative while the bloodstream isolate in the study by Almuzara et al. (4) was found to be weakly oxidase positive, similar to our isolate.

As these characterizations further suggest greater consistency with identification of *P. fulva*, subsequent verification using the more reliable 16S rRNA gene sequencing method in all three cases corroborated the findings by showing that all three isolates had the highest identity with *P. fulva*. Further comparisons of antibiotic profiles of the three isolated samples revealed subtle differences, which highlighted the potential variability in *P. fulva* susceptibility. In the Seok et al. case report (3), the organism was susceptible to piperacillin-tazobactam, ceftazidime, cefotaxime, aztreonam, cefepime, imipenem, meropenem, gentamicin, tobramycin, amikacin, and levofloxacin. However, it demonstrated resistance to chloramphenicol and trimethoprim-sulfamethoxazole when tested by the Etest (3). Our own strain showed a susceptibility profile similar to that of Seok et al. In contrast, the isolate from the report of Almuzara et al. showed susceptibility to cefepime, cefepime plus lithium clavulanate, amikacin, ciprofloxacin, and colistin but resistance to ceftazidime, ceftazidime plus lithium clavulanate, piperacillin-tazobactam, imipenem, meropenem, and gentamicin. Further assessment with EDTA-sodium mercaptoacetic acid (EDTA-SMA) double-disc assays was performed with imipenem and meropenem, to which the *P. fulva* strain tested susceptible, thus indicating the possible presence of metallo-β-lactamase (MBL). Additional PCR amplification studies showed that the *P. fulva* isolate did indeed contain the *bla*<sub>VIM</sub> gene (4). Integration of the MBL cassette into this isolate raises the concern of possible transmission of these resistance-inducing cassettes across different *Pseudomonas* species, including *P. fulva*.

Although *P. fulva* has traditionally been described within the context of rice and petroleum fields, studies have shown a broad range of environments in which the organism can survive. In a study designed to collect samples from 80 “habitat types” that represented a diversity of microenvironments ranging from vertebrate skin to bathroom counter surfaces in 20 households, *P. fulva* was among the four most commonly encountered *Pseudomonas* species (6). Since *P. fulva* is commonly found in the environment, there is potential for it to be identified from clinical specimens. As the *P. fulva* in the present study was isolated concomitantly with *Enterobacter cloacae*, there is strong reason to believe that the *P. fulva* was hospital acquired. Our case further highlights the possible emergence of *P. fulva* in the hospital setting and the need for circumspect diagnosis in the setting of phenotypic and biochemical inconsistencies with automated identification.

**ACKNOWLEDGMENTS**

We thank Theresa Stanley at Children’s Healthcare of Atlanta for performing identification of our isolate using the Microflex LT MALDI-TOF mass spectrometer and John Varga at Emory University School of Medicine Rollins Research Center for performing the Biolog identification.

**REFERENCES**

1. CLSI. Interpretive criteria for identification of bacteria and fungi by DNA target sequencing: approved guideline. CLSI document MM18-A. Clinical and Laboratory Standards Institute, Wayne, PA.